|
|
Ovarian cancer is the deadliest of gynecological cancers and the
fourth-leading cause of cancer death among American women. In 2005, it
is estimated that over 22,000 women will be diagnosed with the disease
and more than 16,000 will lose their lives to it. Although ovarian
cancer is most common in women over the age of 50, it can affect women
of any age.
Cancer of the ovary, a disease affecting one of both of the ovaries, is
one of the most serious and under-recognized ailments affecting women.
In United States, it is considered as the fifth among the most fatal
gynecologic cancers (affecting the female reproductive organs). It is
said that in every 57 women, one may be diagnosed with ovarian cancer
and almost half of those women diagnosed with the said cancer may die
in a span of five years.
Ovarian cancer, a condition characterized by an overgrowth of malignant
cells in one or both of the ovaries, is one of the deadliest and
under-recognized cancers affecting women. Every year, there are more
than 25,000 women that suffer from this deadly disease. Half of them
are most likely to die within a period of five years.
A hysterectomy is not often a procedure that needs to be performed
urgently, except in the case of cancer. Therefore, a woman considering
the procedure should take time to investigate all her options,
including other possible treatments. There are now new treatments for
conditions that previously would have required a hysterectomy. Women
advised to have a hysterectomy for a non-cancerous condition before
being offered more conservative treatments may find it beneficial to
seek a second opinion.
OvaRex®
MAb is a monoclonal antibody – a biotech drug – designed to help the
patient’s immune system recognize and more effectively fight ovarian
cancer. OvaRex® MAb is given during the ‘watchful waiting’ period,
following successful front-line therapy. It may become recognized as
the most significant advance in ovarian cancer treatment since the use
of chemotherapy to treat this illness.
Ovarian
cancer is an illness that progresses quickly. Discover why one female
doctor calls a woman's ovaries her female balls, and her unique view on
what they may be saying when they develop cancer. Also, find out what
common ingredient reduced a woman's risk of ovarian cancer by 46%.
Two Percent of All Female Newborns in the United States Are at Risk of Getting Ovarian Cancer As many as 30,000 U.S. women will be diagnosed with ovarian cancer this
year. In 2006, between 15,000 and 16,000 women are likely to die from
this silent killer. Ovarian cancer is the 5th leading cause of death
among women, and it is responsible for about five percent of all cancer
deaths. Chances are your doctor may have misdiagnosed you. That is
often the case. A recent British study found 60 percent of all U.K.
general practitioners had misdiagnosed their patients. Three-quarters
of British doctors surveyed incorrectly assumed that symptoms only
occurred in the late stages of ovarian cancer. Based upon that
information, it should be no surprise that Britain has one of the
lowest survival rates for ovarian cancer in the Western World – of
6,800 cases diagnosed each year, more than 4,600 die.
A large clinical test shows that giving chemotherapy directly into the
stomach, as well as into a vein, can improve survival of women with
advanced ovarian cancer by about sixteen months. The results of the
study, which pop up in this week's issue of the New England Journal of
Medicine, prompted the National Cancer Institute to issue a statement
supporting doctors to employ this plan of attack for appropriate
patients.
|
|